Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

Summary

This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a single intravenous infusion in healthy adult subjects. Four sequential dose cohorts will be evaluated, each with sentinel dosing and SRC-reviewed dose escalation.

Timeline

Start

2026-06-10

Primary completion

2026-09

Completion

2026-09

Drugs

Indications